WT1
MCID: WLM013
MIFTS: 68

Wilms Tumor 1 (WT1)

Categories: Cancer diseases, Fetal diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Wilms Tumor 1

MalaCards integrated aliases for Wilms Tumor 1:

Name: Wilms Tumor 1 58 76 30 6
Nephroblastoma 58 12 54 60 38 30 6 15 74
Wilms Tumor 58 60 45 15
Wilms' Tumor 12 77 54
Wt1 58 54 76
Bilateral Wilms Tumor 54 74
Renal Wilms' Tumor 12 15
Nonanaplastic Renal Wilm's Tumor 12
Nonanaplastic Kidney Wilms Tumor 74
Nonanaplastic Renal Wilms Tumor 12
Childhood Renal Wilms' Cancer 12
Childhood Kidney Wilms Tumor 74
Childhood Renal Wilms Tumor 12
Adult Renal Wilms' Tumor 12
Adult Kidney Wilms Tumor 74
Renal Embryonic Tumor 60
Wilms Tumor, Somatic 58
Adult Nephroblastoma 12
Wilms Tumor, Type 1 58
Renal Wilms Tumor 12
Wilms Tumor-1 13

Characteristics:

Orphanet epidemiological data:

60
nephroblastoma
Inheritance: Autosomal dominant,Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (United Kingdom),1-5/10000 (Europe); Age of onset: Childhood; Age of death: any age;

OMIM:

58
Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
genetic heterogeneity
majority of wilms tumors are sporadic
onset between 2-5 years
rare adult cases reported
5-10% of all wilms tumor are bilateral
21% of hereditary wilms tumor are bilateral
associated with several congenital malformation syndromes (wagr , abnormal urogenital development syndromes)
two-step mutation hypothesis (germline mutation followed by somatic mutation or two sequential somatic mutations)
loss of tumor suppressor gene
associated with several loci on chromosomes 11p15 (wt2, ), 16 (wt3, ), 17 (wt4, ), and 7 (wt5, ).



Classifications:

Orphanet: 60  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:2154 DOID:5176
OMIM 58 194070
KEGG 38 H02301
MeSH 45 D009396
SNOMED-CT 69 25081006 31470003
MESH via Orphanet 46 D009396
ICD10 via Orphanet 35 C64
UMLS via Orphanet 75 C0027708
Orphanet 60 ORPHA654
MedGen 43 C0027708

Summaries for Wilms Tumor 1

NIH Rare Diseases : 54 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 654Disease definitionNephroblastoma is the most frequent malignant renal tumor in children and is associated with an abnormal proliferation of cells that resemble the kidney cells of an embryo (metanephroma), leading to the term embryonal tumor.EpidemiologyThe annual incidence is estimated at about 1/10,000 births and it affects boys as well as girls.Clinical descriptionNephroblastoma mainly affects young children, between the ages 1 and 5 years, but 15% of nephroblastomas occur before the age of 1 year and 2% after the age of 8 years. Adult forms are very rare. An abdominal mass (unilateral in most cases) is frequently present. Patients sometimes experience abdominal pain (around 10% of cases), hypertension, fever (20% of cases), hematuria and anemia. The evolution of the disease is very rapid, with regional dissemination in the retroperitoneal space, lymph nodes, vessels (renal vein and inferior vena cava) and in the peritoneal cavity in cases of tumor effraction, and a strong likelihood of metastases in the lungs and liver.EtiologyNephroblastoma is sporadic in 99% of cases and, among these cases, 10% are associated with congenital anomalies (aniridia, hemihypertrophy, genitourinary defects) or form part of specific syndromes (Beckwith-Wiedemann, Denys-Drash, WAGR or Perlman syndromes; see these terms). Genetic anomalies found in different chromosomal regions, including 11p13 (containing the WT1 gene), 11p15.5 (containing the H19 gene), 16q, 1p, 1q and 17p, have been found within the tumors. Familial forms are very rare (1% of cases) and are transmitted in an autosomal dominant fashion.Diagnostic methodsDiagnosis is based on imagery, particularly CT or MRI scans. The concentration of urinary metabolites of catecholamines is normal. Analysis of the extent of the disease is also conducted using imagery (ultrasound and abdominal CT analyzing particularly the liver and contralateral kidney, and thoracic radiography and CT).Differential diagnosisDifferential diagnoses include other renal tumors in children such as mesoblastic nephroma (especially in infants), clear cell sarcoma, neuroblastoma (extremely rare in the kidney but may invade the kidney by contiguity), rhabdoid tumors (see these terms) and metanephric stromal tumors.Management and treatmentDisease management is multidisciplinary and may involve chemotherapy and surgery with or without radiotherapy. Chemotherapy enables preoperative reduction in tumor size and eradicates metastases. Surgery should be accomplished without tumor effraction, which usually means that total nephrectomy is required. Nephroblastoma can be confirmed on microscopic examination, which also allows the stage of the tumor in the kidney to be evaluated. This in turn determines the choice of post-operative chemotherapy. Radiotherapy is reserved for the most extensive cases or cases with the least favorable histology.PrognosisIn the majority of cases, the prognosis is favorable with a survival rate of over 90%. Adult forms have the same prognosis and should be treated following the same methods, even when adult patients tolerate chemotherapy less well than children (which may lead to a reduction in treatment and as a result a worse prognosis).Visit the Orphanet disease page for more resources.

MalaCards based summary : Wilms Tumor 1, also known as nephroblastoma, is related to meacham syndrome and wilms tumor, aniridia, genitourinary anomalies, and mental retardation syndrome, and has symptoms including abdominal pain An important gene associated with Wilms Tumor 1 is WT1 (WT1 Transcription Factor), and among its related pathways/superpathways are DNA Damage and BRCA1 Pathway. The drugs Dactinomycin and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include kidney, myeloid and t cells, and related phenotypes are abdominal pain and nephroblastoma

Disease Ontology : 12 A kidney cancer that affects the kidneys and typically located in children.

OMIM : 58 Wilms tumor is the most common renal tumor of childhood, occurring with an incidence of 1 in 10,000 and with a median age of diagnosis between 3 and 4 years of age. Wilms tumours are thought to develop from abnormally persistent embryonal cells within nephrogenic rests. Histologically, Wilms tumor mirrors the development of the normal kidney and classically consists of 3 cell types: blastema, epithelia, and stroma (summary by Slade et al., 2010). (194070)

UniProtKB/Swiss-Prot : 76 Wilms tumor 1: Embryonal malignancy of the kidney that affects approximately 1 in 10'000 infants and young children. It occurs both in sporadic and hereditary forms.

Wikipedia : 77 Wilms'' tumor, also known as nephroblastoma, is a cancer of the kidneys that typically occurs in... more...

Related Diseases for Wilms Tumor 1

Diseases in the Hereditary Wilms' Tumor family:

Wilms Tumor 1 Wilms Tumor 2
Wilms Tumor 3 Wilms Tumor 4
Wilms Tumor 5 Wilms Tumor 6
Familial Wilms Tumor 2

Diseases related to Wilms Tumor 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 517)
# Related Disease Score Top Affiliating Genes
1 meacham syndrome 33.2 WT1 WT1-AS
2 wilms tumor, aniridia, genitourinary anomalies, and mental retardation syndrome 32.9 IGF2 WT1 WT1-AS
3 cerebellar angioblastoma 32.7 TP53 WT1
4 ovarian cancer 1 32.6 BRCA2 TP53 WT1
5 hereditary wilms' tumor 32.6 IGF2 REST WT1
6 li-fraumeni syndrome 2 32.4 CHEK2 TP53
7 li-fraumeni syndrome 32.4 BRCA2 CHEK2 TP53
8 malignant ovarian surface epithelial-stromal neoplasm 32.2 BRCA2 TP53 WT1
9 ovary epithelial cancer 32.2 BRCA2 TP53 WT1
10 leiomyosarcoma 32.1 IGF2 TP53 WT1
11 rhabdoid tumor predisposition syndrome 1 32.0 IGF2 TP53 WT1
12 female reproductive endometrioid cancer 31.9 TP53 WT1
13 hemihyperplasia, isolated 31.8 H19 IGF2 WT1
14 wilson-turner x-linked mental retardation syndrome 31.6 IGF2 POU6F2 WT1 WT1-AS
15 beckwith-wiedemann syndrome 31.5 GPC3 H19 IGF2 IGF2-AS TP53 WT1
16 leukemia, acute myeloid 30.8 MEG3 TP53 WT1 WT1-AS
17 hepatoblastoma 30.6 GPC3 H19 IGF2 TP53
18 glioma 30.4 BRCA2 H19 MEG3 TP53
19 wilms tumor 2 30.2 H19 KCNQ1DN
20 adrenocortical carcinoma, hereditary 30.1 CHEK2 H19 IGF2 TP53
21 ovarian epithelial cancer 30.0 H19 MEG3
22 medulloblastoma 30.0 BRCA2 H19 IGF2 REST TP53
23 kidney cancer 29.9 H19 MEG3 TP53
24 osteogenic sarcoma 29.9 CHEK2 H19 MEG3 TP53
25 silver-russell syndrome 29.8 H19 IGF2 MEG3
26 hepatocellular carcinoma 29.8 GPC3 H19 IGF2 IGF2-AS MEG3 TP53
27 prostate cancer 29.6 BRCA2 CHEK2 H19 IGF2 IGF2-AS MEG3
28 cervical wilms' tumor 12.4
29 wilms tumor and radial bilateral aplasia 12.3
30 wilms tumor predisposition 12.3
31 wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome 12.3
32 wilms tumor 3 12.2
33 stromal predominant kidney wilms' tumor 12.2
34 global developmental delay, lung cysts, overgrowth, and wilms tumor 12.2
35 mixed cell type kidney wilms' tumor 12.2
36 blastema predominant kidney wilms' tumor 12.2
37 metachronous kidney wilms' tumor 12.2
38 nephrotic syndrome, type 4 12.0
39 mulibrey nanism 11.6
40 focal segmental glomerulosclerosis 11.5
41 diffuse mesangial sclerosis 11.5
42 ewing sarcoma 11.4
43 endometrial cancer 11.4
44 kidney disease 11.4
45 pseudohermaphroditism 11.4
46 clear cell sarcoma 11.4
47 congenital mesoblastic nephroma 11.4
48 wilms tumor 4 11.3
49 gonadal dysgenesis 11.3
50 gonadoblastoma 11.3

Graphical network of the top 20 diseases related to Wilms Tumor 1:



Diseases related to Wilms Tumor 1

Symptoms & Phenotypes for Wilms Tumor 1

Human phenotypes related to Wilms Tumor 1:

60 33 (show all 11)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abdominal pain 60 33 hallmark (90%) Very frequent (99-80%) HP:0002027
2 nephroblastoma 60 33 hallmark (90%) Very frequent (99-80%) HP:0002667
3 hypertension 60 33 occasional (7.5%) Occasional (29-5%) HP:0000822
4 fever 60 33 occasional (7.5%) Occasional (29-5%) HP:0001945
5 weight loss 60 33 occasional (7.5%) Occasional (29-5%) HP:0001824
6 hematuria 60 33 occasional (7.5%) Occasional (29-5%) HP:0000790
7 neoplasm of the lung 60 33 occasional (7.5%) Occasional (29-5%) HP:0100526
8 lymphadenopathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0002716
9 aniridia 60 33 occasional (7.5%) Occasional (29-5%) HP:0000526
10 neoplasm of the liver 60 33 occasional (7.5%) Occasional (29-5%) HP:0002896
11 neoplasm 60 Very frequent (99-80%)

Symptoms via clinical synopsis from OMIM:

58
Genitourinary Kidneys:
nephroblastoma

Neoplasia:
nephroblastoma

Clinical features from OMIM:

194070

UMLS symptoms related to Wilms Tumor 1:


abdominal pain

MGI Mouse Phenotypes related to Wilms Tumor 1:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.56 BRCA2 GPC3 IGF2 REST TP53 TRIM28
2 limbs/digits/tail MP:0005371 9.02 BRCA2 GPC3 IGF2 TP53 TRIP13

Drugs & Therapeutics for Wilms Tumor 1

Drugs for Wilms Tumor 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 295)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dactinomycin Approved, Investigational Phase 4,Phase 3,Phase 2 50-76-0 457193 2019
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 6055-19-2, 50-18-0 2907
4
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
6
Itraconazole Approved, Investigational Phase 4,Phase 3,Not Applicable 84625-61-6 55283
7
Oxytetracycline Approved, Investigational, Vet_approved Phase 4 79-57-2 54715139 5280972
8
Epirubicin Approved Phase 4,Phase 2 56420-45-2 41867
9
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
10
Pirarubicin Investigational Phase 4 72496-41-4
11 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
12 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
16 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
18 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
19 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
21 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
24 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25
Hydroxyitraconazole Phase 4,Phase 3,Not Applicable
26 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
28 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
32
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
33
Decitabine Approved, Investigational Phase 2, Phase 3,Phase 1 2353-33-5 451668
34
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
35
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
36
Morphine Approved, Investigational Phase 3 57-27-2 5288826
37
Cytarabine Approved, Experimental, Investigational Phase 2, Phase 3,Phase 3,Phase 1 147-94-4, 65-46-3 6253
38
Idarubicin Approved Phase 2, Phase 3,Phase 3 58957-92-9 42890
39
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
40
Sulfamethoxazole Approved Phase 3 723-46-6 5329
41
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
42
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1 75607-67-9, 21679-14-1 30751
43
Mycophenolic acid Approved Phase 3 24280-93-1 446541
44
Captopril Approved Phase 3 62571-86-2 44093
45
Palivizumab Approved, Investigational Phase 3 188039-54-5
46
Ribavirin Approved Phase 3 36791-04-5 37542
47
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
48
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
49
Caspofungin Approved Phase 3,Not Applicable 179463-17-3, 162808-62-0 2826718 468682
50
Acyclovir Approved Phase 3 59277-89-3 2022

Interventional clinical trials:

(show top 50) (show all 265)
# Name Status NCT ID Phase Drugs
1 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
2 Combination Therapy of Anthracyclines for Children With Nephroblastoma Not yet recruiting NCT03892330 Phase 4 Vincristine;Oxytetracycline/ Cyclophosphamide;Liposomal doxorubicin;Doxorubicin;Pharmorubicin;Pirarubicin
3 Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor Unknown status NCT00003804 Phase 3 vincristine sulfate
4 Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
5 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
6 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Unknown status NCT01987596 Phase 3
7 Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia Unknown status NCT02171117 Phase 3
8 WT1 for the Detection of Minimal Residual Disease Completed NCT00179829 Phase 2, Phase 3
9 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Completed NCT00379340 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;cyclophosphamide;etoposide
10 Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Completed NCT00352534 Phase 3 vincristine sulfate;doxorubicin hydrochloride
11 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Completed NCT00945009 Phase 3 Doxorubicin Hydrochloride;Vincristine Sulfate
12 Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors Completed NCT00002610 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
13 Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer Completed NCT00002611 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
14 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid
15 Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML) Completed NCT00909168 Phase 2, Phase 3 FLAIMy - Fluda, Ida, Ara-C, Mylotarg
16 Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk Completed NCT00860639 Phase 3 gemtuzumab ozogamycin
17 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
18 HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk Completed NCT02461121 Phase 3 cyclosporine A;Mycophenolate mofetil;Ara-C;fludarabine;anti-lymphocyte globulin;cyclophosphamide
19 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
20 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
21 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
22 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
23 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
24 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
25 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
26 A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old Completed NCT00927498 Phase 3 conventional chemotherapy (AraC + Daunorubicin),;Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
27 Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4 Recruiting NCT02473146 Phase 2, Phase 3 Gemtuzumab ozogamicin (GO)
28 Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors Active, not recruiting NCT01751997 Phase 2, Phase 3 Transplants from 8/8-matched Unrelated donors;Transplants from family-mismatched/haploidentical donors
29 Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm) Not yet recruiting NCT03669783 Phase 3 treatment Vincristin;treatment Actinomycin-D;treatment Doxorubicin;treatment Carboplatin;Etoposide
30 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
31 Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia Unknown status NCT01513109 Phase 1, Phase 2
32 WT1 Peptid Vaccination in Carcinomas Unknown status NCT00153608 Phase 2
33 WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) Unknown status NCT00153582 Phase 2
34 Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney Unknown status NCT00025103 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;melphalan;vincristine sulfate
35 Dendritic Cell Vaccination for Patients With Solid Tumors Unknown status NCT01291420 Phase 1, Phase 2
36 Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma Unknown status NCT00965224 Phase 2
37 Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT Unknown status NCT01956630 Phase 1, Phase 2
38 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
39 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
40 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
41 A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients Completed NCT02550535 Phase 1, Phase 2
42 Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy Completed NCT00433745 Phase 2 WT1 Peptide Vaccine
43 WT-1 Analog Peptide Vaccine in Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Completed NCT01266083 Phase 2
44 WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy Completed NCT01265433 Phase 2
45 WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study Completed NCT01621724 Phase 1, Phase 2
46 A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor Completed NCT00187031 Phase 2 Topotecan, Filgrastim (G-CSF), Pegfilgrastim
47 WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation Completed NCT01334060 Phase 2
48 Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Completed NCT00923910 Phase 1, Phase 2 WT1 Peptide-Pulsed Dendritic Cells;Donor Lymphocytes;IL-4;KLH;WT1 Peptides;Endotoxin;Diphenhydramine;Acetaminophen
49 Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers Completed NCT00488592 Phase 2 GM-CSF (Sargramostim)
50 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate

Search NIH Clinical Center for Wilms Tumor 1

Cochrane evidence based reviews: wilms tumor

Genetic Tests for Wilms Tumor 1

Genetic tests related to Wilms Tumor 1:

# Genetic test Affiliating Genes
1 Wilms Tumor 1 30 BRCA2 GPC3 GPC4 H19 IGF2 WT1
2 Nephroblastoma 30

Anatomical Context for Wilms Tumor 1

MalaCards organs/tissues related to Wilms Tumor 1:

42
Kidney, Myeloid, T Cells, Bone, Bone Marrow, Lymph Node, Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Wilms Tumor 1:

20
Children

Publications for Wilms Tumor 1

Articles related to Wilms Tumor 1:

(show top 50) (show all 280)
# Title Authors Year
1
A case of ovarian teratoma with nephroblastoma presenting spontaneous rupture. ( 30701637 )
2019
2
Physiological functions of Wilms' tumor 1-associating protein and its role in tumourigenesis. ( 30756410 )
2019
3
The cell tube block technique and an immunohistochemistry panel including Wilms tumor 1 to assist in diagnosing cavitary effusions in dogs and cats. ( 30865320 )
2019
4
Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer. ( 30306202 )
2019
5
Wilms Tumor-1 (WT1) rs16754 Polymorphism ( 30520285 )
2019
6
Inhibition of Heme Oxygenase-1 Activity Enhances Wilms Tumor-1-Specific T-Cell Responses in Cancer Immunotherapy. ( 30678050 )
2019
7
Wilms tumor 1 expression: addressing the 'elephant' in MDS. ( 30714447 )
2019
8
Educational Case: Wilms Tumor (Nephroblastoma). ( 30733996 )
2019
9
Loss of Wilms tumor 1 protein is a marker for apoptosis in response to replicative stress in leukemic cells. ( 29589053 )
2018
10
Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability. ( 29482572 )
2018
11
Immunoreactivity of Wilms tumor 1 (WT1) as an additional evidence supporting hemangiomatous rather than inflammatory origin in the etiopathogenesis of angiolymphoid hyperplasia with eosinophilia. ( 29445571 )
2018
12
Wilms' Tumor 1 Overexpression in Granulosa Cells Is Associated with Polycystic Ovaries in Polycystic Ovary Syndrome Patients. ( 29414825 )
2018
13
Quantification of Wilms' tumor 1 mRNA by digital polymerase chain reaction. ( 28994041 )
2018
14
Sensitive detection of rare antigen-specific T cells directed against Wilms' tumor 1 by FluoroSpot assay. ( 28573960 )
2018
15
Outcomes of measurable residual disease in pediatric acute myeloid leukemia pre- and post-hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and Wilms tumor 1 gene expression. ( 29933069 )
2018
16
Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation. ( 29753838 )
2018
17
Description of mutation spectrum and polymorphism of Wilms' tumor 1 (WT1) gene in hypospadias patients in the Indonesian population. ( 29958641 )
2018
18
Prognostic significance of The Wilms' Tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia. ( 29407184 )
2018
19
Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma. ( 30008944 )
2018
20
Wilms' tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90. ( 30143009 )
2018
21
A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. ( 30430205 )
2018
22
Wilm's tumor-1 (WT1) rs16754 polymorphism and clinical outcome in acute myeloid leukemia. ( 30468432 )
2018
23
Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study. ( 30082223 )
2018
24
Wilms' tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease. ( 30135315 )
2018
25
The antitumor effect of static and extremely low frequency magnetic fields against nephroblastoma and neuroblastoma. ( 29719057 )
2018
26
Reply to GATA3 differential expression in neuroblastoma and nephroblastoma. ( 29131532 )
2018
27
GATA3 differential expression in neuroblastoma and nephroblastoma. ( 29131553 )
2018
28
Variability in Imaging Practices and Comparative Cumulative Effective Dose for Neuroblastoma and Nephroblastoma Patients at 6 Pediatric Oncology Centers. ( 28697171 )
2018
29
Overexpression of Wilms' tumor 1 in skin lesions of psoriasis is associated with abnormal proliferation and apoptosis of keratinocytes. ( 30132523 )
2018
30
Wilms' tumor 1 (WT1) as a prognosis factor in gynecological cancers: A meta-analysis. ( 29995811 )
2018
31
Multifocal Spinal Cord Nephroblastoma in a Dog. ( 29422310 )
2018
32
A blastema-predominant canine renal nephroblastoma with gingival metastasis: case report and literature review. ( 29528810 )
2018
33
Nephroblastoma in bester sturgeon, a cultured hybrid of Huso huso × Acipenser ruthenus: Diagnostic imaging, clinical and histopathological study. ( 29542819 )
2018
34
Partial Nephrectomy for Nephroblastoma: A National Cancer Data Base Review. ( 29559046 )
2018
35
Childhood nephroblastoma in Southern and Eastern Europe and the US: Incidence variations and temporal trends by human development index. ( 29655086 )
2018
36
MiR-429 regulates the proliferation and apoptosis of nephroblastoma cells through targeting c-myc. ( 30178838 )
2018
37
Analysis of prognostic factors of nephroblastoma in a Tunisian cohort. ( 30325488 )
2018
38
A case report of infantile cystic nephroblastoma. ( 30368245 )
2018
39
Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein. ( 28299466 )
2017
40
Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. ( 28067876 )
2017
41
Nephron, Wilms' tumor-1 (WT1), and synaptopodin expression in developing podocytes of mice. ( 28179596 )
2017
42
Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. ( 29100432 )
2017
43
Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis. ( 28054314 )
2017
44
Significance of Wilms' tumor 1 antigen as a cancer vaccine for pancreatic cancer. ( 28950074 )
2017
45
Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology. ( 28369773 )
2017
46
Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome. ( 27866185 )
2017
47
Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification. ( 27922671 )
2017
48
Nucleotide Transition 390C-T in the Wilms' Tumor 1 Gene: A Risk Factor of Hypospadias? ( 28878596 )
2017
49
Transcription factor Wilms' tumor 1 regulates developmental RNAs through 3' UTR interaction. ( 28289143 )
2017
50
Quantitative assessment of Wilms tumor 1 expression by real-time quantitative polymerase chain reaction in patients with acute myeloblastic leukemia. ( 28567073 )
2017

Variations for Wilms Tumor 1

UniProtKB/Swiss-Prot genetic disease variations for Wilms Tumor 1:

76
# Symbol AA change Variation ID SNP ID
1 WT1 p.Pro181Ser VAR_007739 rs2234584
2 WT1 p.Ser223Asn VAR_007740
3 WT1 p.Gly253Ala VAR_007741
4 WT1 p.Arg366Cys VAR_007745
5 WT1 p.Arg366His VAR_007746
6 WT1 p.His373Gln VAR_007747
7 WT1 p.Arg394Trp VAR_007750
8 WT1 p.Cys355Gly VAR_043799
9 WT1 p.Arg394Leu VAR_043807

ClinVar genetic disease variations for Wilms Tumor 1:

6 (show top 50) (show all 762)
# Gene Variation Type Significance SNP ID Assembly Location
1 WT1 NM_024426.5(WT1): c.123G> C (p.Pro41=) single nucleotide variant Benign/Likely benign rs555140661 GRCh37 Chromosome 11, 32456784: 32456784
2 WT1 NM_024426.5(WT1): c.123G> C (p.Pro41=) single nucleotide variant Benign/Likely benign rs555140661 GRCh38 Chromosome 11, 32435238: 32435238
3 WT1 NM_024426.5(WT1): c.345C> T (p.Pro115=) single nucleotide variant Benign rs1799925 GRCh37 Chromosome 11, 32456562: 32456562
4 WT1 NM_024426.5(WT1): c.345C> T (p.Pro115=) single nucleotide variant Benign rs1799925 GRCh38 Chromosome 11, 32435016: 32435016
5 GPC3 NM_004484.3(GPC3): c.1398G> A (p.Leu466=) single nucleotide variant Conflicting interpretations of pathogenicity rs745968470 GRCh37 Chromosome X, 132795773: 132795773
6 GPC3 NM_004484.3(GPC3): c.1398G> A (p.Leu466=) single nucleotide variant Conflicting interpretations of pathogenicity rs745968470 GRCh38 Chromosome X, 133661745: 133661745
7 WT1 NM_024426.5(WT1): c.1131T> C (p.Pro377=) single nucleotide variant Conflicting interpretations of pathogenicity rs151034312 GRCh37 Chromosome 11, 32417936: 32417936
8 WT1 NM_024426.5(WT1): c.1131T> C (p.Pro377=) single nucleotide variant Conflicting interpretations of pathogenicity rs151034312 GRCh38 Chromosome 11, 32396390: 32396390
9 WT1 NM_024426.5(WT1): c.1122A> G (p.Arg374=) single nucleotide variant Benign rs16754 GRCh37 Chromosome 11, 32417945: 32417945
10 WT1 NM_024426.5(WT1): c.1122A> G (p.Arg374=) single nucleotide variant Benign rs16754 GRCh38 Chromosome 11, 32396399: 32396399
11 WT1 NM_024426.4(WT1): c.878_894del17 (p.Asn293Ilefs) deletion Pathogenic rs587776573 GRCh38 Chromosome 11, 32417633: 32417649
12 WT1 NM_024426.4(WT1): c.878_894del17 (p.Asn293Ilefs) deletion Pathogenic rs587776573 GRCh37 Chromosome 11, 32439179: 32439195
13 WT1 NM_024426.4(WT1): c.1079delG (p.Gly360Valfs) deletion Pathogenic rs587776574 GRCh38 Chromosome 11, 32399967: 32399967
14 WT1 NM_024426.4(WT1): c.1079delG (p.Gly360Valfs) deletion Pathogenic rs587776574 GRCh37 Chromosome 11, 32421513: 32421513
15 WT1 NM_024426.4(WT1): c.1384C> T (p.Arg462Trp) single nucleotide variant Pathogenic rs121907900 GRCh37 Chromosome 11, 32413566: 32413566
16 WT1 NM_024426.4(WT1): c.1384C> T (p.Arg462Trp) single nucleotide variant Pathogenic rs121907900 GRCh38 Chromosome 11, 32392020: 32392020
17 WT1 NM_024426.5(WT1): c.1447+5G> A single nucleotide variant Pathogenic rs587776576 GRCh38 Chromosome 11, 32391967: 32391967
18 WT1 NM_024426.5(WT1): c.1447+5G> A single nucleotide variant Pathogenic rs587776576 GRCh37 Chromosome 11, 32413513: 32413513
19 WT1 NM_024426.4(WT1): c.1372C> T (p.Arg458Ter) single nucleotide variant Pathogenic rs121907909 GRCh37 Chromosome 11, 32413578: 32413578
20 WT1 NM_024426.4(WT1): c.1372C> T (p.Arg458Ter) single nucleotide variant Pathogenic rs121907909 GRCh38 Chromosome 11, 32392032: 32392032
21 WT1 NM_024426.4(WT1): c.1288C> T (p.Arg430Ter) single nucleotide variant Pathogenic rs121907906 GRCh37 Chromosome 11, 32414263: 32414263
22 WT1 NM_024426.4(WT1): c.1288C> T (p.Arg430Ter) single nucleotide variant Pathogenic rs121907906 GRCh38 Chromosome 11, 32392717: 32392717
23 WT1 NM_024426.4(WT1): c.531C> A (p.Tyr177Ter) single nucleotide variant Pathogenic rs121907911 GRCh37 Chromosome 11, 32456361: 32456361
24 WT1 NM_024426.4(WT1): c.531C> A (p.Tyr177Ter) single nucleotide variant Pathogenic rs121907911 GRCh38 Chromosome 11, 32434815: 32434815
25 BRCA2 NM_000059.3(BRCA2): c.658_659delGT (p.Val220Ilefs) deletion Pathogenic rs80359604 GRCh37 Chromosome 13, 32903606: 32903607
26 BRCA2 NM_000059.3(BRCA2): c.658_659delGT (p.Val220Ilefs) deletion Pathogenic rs80359604 GRCh38 Chromosome 13, 32329469: 32329470
27 BRCA2 NM_000059.3(BRCA2): c.5645C> G (p.Ser1882Ter) single nucleotide variant Pathogenic rs80358785 GRCh37 Chromosome 13, 32914137: 32914137
28 BRCA2 NM_000059.3(BRCA2): c.5645C> G (p.Ser1882Ter) single nucleotide variant Pathogenic rs80358785 GRCh38 Chromosome 13, 32340000: 32340000
29 GPC3 NM_004484.3(GPC3): c.595C> T (p.Arg199Ter) single nucleotide variant Pathogenic rs104894855 GRCh37 Chromosome X, 132887946: 132887946
30 GPC3 NM_004484.3(GPC3): c.595C> T (p.Arg199Ter) single nucleotide variant Pathogenic rs104894855 GRCh38 Chromosome X, 133753919: 133753919
31 GPC3 NM_004484.3(GPC3): c.361C> T (p.His121Tyr) single nucleotide variant Pathogenic rs122453119 GRCh37 Chromosome X, 132888180: 132888180
32 GPC3 NM_004484.3(GPC3): c.361C> T (p.His121Tyr) single nucleotide variant Pathogenic rs122453119 GRCh38 Chromosome X, 133754153: 133754153
33 GPC3 NM_004484.3(GPC3): c.1705G> A (p.Ala569Thr) single nucleotide variant Pathogenic rs122453120 GRCh37 Chromosome X, 132670190: 132670190
34 GPC3 NM_004484.3(GPC3): c.1705G> A (p.Ala569Thr) single nucleotide variant Pathogenic rs122453120 GRCh38 Chromosome X, 133536162: 133536162
35 GPC3 NM_004484.3(GPC3): c.1159C> T (p.Arg387Ter) single nucleotide variant Pathogenic rs122453121 GRCh37 Chromosome X, 132833930: 132833930
36 GPC3 NM_004484.3(GPC3): c.1159C> T (p.Arg387Ter) single nucleotide variant Pathogenic rs122453121 GRCh38 Chromosome X, 133699902: 133699902
37 BRCA2 NM_000059.3(BRCA2): c.5682C> G (p.Tyr1894Ter) single nucleotide variant Pathogenic rs41293497 GRCh37 Chromosome 13, 32914174: 32914174
38 BRCA2 NM_000059.3(BRCA2): c.5682C> G (p.Tyr1894Ter) single nucleotide variant Pathogenic rs41293497 GRCh38 Chromosome 13, 32340037: 32340037
39 BRCA2 NM_000059.3(BRCA2): c.7480C> T (p.Arg2494Ter) single nucleotide variant Pathogenic rs80358972 GRCh37 Chromosome 13, 32930609: 32930609
40 BRCA2 NM_000059.3(BRCA2): c.7480C> T (p.Arg2494Ter) single nucleotide variant Pathogenic rs80358972 GRCh38 Chromosome 13, 32356472: 32356472
41 BRCA2 NM_000059.3(BRCA2): c.9117G> A (p.Pro3039=) single nucleotide variant Pathogenic rs28897756 GRCh37 Chromosome 13, 32954050: 32954050
42 BRCA2 NM_000059.3(BRCA2): c.9117G> A (p.Pro3039=) single nucleotide variant Pathogenic rs28897756 GRCh38 Chromosome 13, 32379913: 32379913
43 WT1 NM_024426.5(WT1): c.1063T> C (p.Cys355Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs142059681 GRCh37 Chromosome 11, 32421544: 32421544
44 WT1 NM_024426.5(WT1): c.1063T> C (p.Cys355Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs142059681 GRCh38 Chromosome 11, 32399998: 32399998
45 BRCA2 NM_000059.3(BRCA2): c.145G> T (p.Glu49Ter) single nucleotide variant Pathogenic rs80358435 GRCh37 Chromosome 13, 32893291: 32893291
46 BRCA2 NM_000059.3(BRCA2): c.145G> T (p.Glu49Ter) single nucleotide variant Pathogenic rs80358435 GRCh38 Chromosome 13, 32319154: 32319154
47 BRCA2 NM_000059.3(BRCA2): c.5857G> T (p.Glu1953Ter) single nucleotide variant Pathogenic rs80358814 GRCh37 Chromosome 13, 32914349: 32914349
48 BRCA2 NM_000059.3(BRCA2): c.5857G> T (p.Glu1953Ter) single nucleotide variant Pathogenic rs80358814 GRCh38 Chromosome 13, 32340212: 32340212
49 BRCA2 NM_000059.3(BRCA2): c.7051G> A (p.Ala2351Thr) single nucleotide variant Uncertain significance rs80358930 GRCh37 Chromosome 13, 32929041: 32929041
50 BRCA2 NM_000059.3(BRCA2): c.7051G> A (p.Ala2351Thr) single nucleotide variant Uncertain significance rs80358930 GRCh38 Chromosome 13, 32354904: 32354904

Cosmic variations for Wilms Tumor 1:

9 (show all 21)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM21398 WT1 kidney,NS,Wilms tumour,unilateral c.461T>C p.F154S 11:32428601-32428601 0
2 COSM21403 WT1 kidney,NS,Wilms tumour,unilateral c.1013C>A p.S338Y 11:32396289-32396289 0
3 COSM21967 WT1 kidney,NS,Wilms tumour,unilateral c.1180C>G p.R394G 11:32392020-32392020 0
4 COSM21401 WT1 kidney,NS,Wilms tumour,unilateral c.1084C>T p.R362* 11:32392717-32392717 0
5 COSM21445 WT1 kidney,NS,Wilms tumour,unilateral c.602G>A p.G201D 11:32428022-32428022 0
6 COSM21417 WT1 kidney,NS,Wilms tumour,unilateral c.1180C>T p.R394W 11:32392020-32392020 0
7 COSM21397 WT1 kidney,NS,Wilms tumour,unilateral c.1168C>T p.R390* 11:32392032-32392032 0
8 COSM21441 WT1 kidney,NS,Wilms tumour,unilateral c.901C>T p.R301* 11:32396401-32396401 0
9 COSM21408 WT1 kidney,NS,Wilms tumour,unilateral c.1096C>T p.R366C 11:32392705-32392705 0
10 COSM21439 WT1 kidney,NS,Wilms tumour,unilateral c.797A>G p.N266S 11:32416490-32416490 0
11 COSM21971 WT1 kidney,NS,Wilms tumour,unilateral c.1112A>G p.K371R 11:32392689-32392689 0
12 COSM44510 TP53 kidney,NS,Wilms tumour,unilateral c.717C>G p.N239K 17:7674246-7674246 0
13 COSM5678 CTNNB1 kidney,NS,Wilms tumour,unilateral c.107A>C p.H36P 3:41224619-41224619 0
14 COSM5667 CTNNB1 kidney,NS,Wilms tumour,unilateral c.134C>T p.S45F 3:41224646-41224646 0
15 COSM5664 CTNNB1 kidney,NS,Wilms tumour,unilateral c.121A>G p.T41A 3:41224633-41224633 0
16 COSM5663 CTNNB1 kidney,NS,Wilms tumour,unilateral c.133T>C p.S45P 3:41224645-41224645 0
17 COSM5692 CTNNB1 kidney,NS,Wilms tumour,unilateral c.134C>A p.S45Y 3:41224646-41224646 0
18 COSM5689 CTNNB1 kidney,NS,Wilms tumour,unilateral c.134C>G p.S45C 3:41224646-41224646 0
19 COSM13168 CTNNB1 kidney,NS,Wilms tumour,unilateral c.104T>C p.I35T 3:41224616-41224616 0
20 COSM250063 AMER1 kidney,NS,Wilms tumour,unilateral c.565C>T p.Q189* 23:64192722-64192722 0
21 COSM28715 AMER1 kidney,NS,Wilms tumour,unilateral c.85G>A p.A29T 23:64193202-64193202 0

Copy number variations for Wilms Tumor 1 from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 24429 1 180300000 185800000 Microamplification CACNA1E Nephroblastoma

Expression for Wilms Tumor 1

Search GEO for disease gene expression data for Wilms Tumor 1.

Pathways for Wilms Tumor 1

Pathways related to Wilms Tumor 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.09 BRCA2 CHEK2 TP53 TRIM28
2
Show member pathways
11.25 BRCA2 CHEK2 TP53
3 10.9 CHEK2 TP53 TRIM28
4 10.34 MEG3 TP53
5 9.32 CHEK2 TP53

GO Terms for Wilms Tumor 1

Biological processes related to Wilms Tumor 1 according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.91 BRCA2 CHEK2 DIS3L2 TP53 WTAP
2 negative regulation of cell proliferation GO:0008285 9.8 DIS3L2 GPC3 REST TP53 WT1
3 positive regulation of transcription, DNA-templated GO:0045893 9.8 BRCA2 CHEK2 REST TP53 TRIM28 WT1
4 negative regulation of cell growth GO:0030308 9.7 MEG3 TP53 WT1
5 cellular response to drug GO:0035690 9.63 CHEK2 REST TP53
6 double-strand break repair GO:0006302 9.61 BRCA2 CHEK2 TRIP13
7 transcription by RNA polymerase II GO:0006366 9.49 POU6F2 TRIP13
8 replicative senescence GO:0090399 9.48 CHEK2 TP53
9 embryonic placenta morphogenesis GO:0060669 9.37 IGF2 TRIM28
10 response to gamma radiation GO:0010332 9.33 BRCA2 CHEK2 TP53
11 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.13 BRCA2 CHEK2 TP53
12 meiotic recombination checkpoint GO:0051598 8.96 TRIP13
13 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 BRCA2 CHEK2 TP53

Sources for Wilms Tumor 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....